Evopoint Biosciences(688837.SH): Clinical trial application for XNW26018 tablets approved by the National Medical Products Administration

Evopoint Biosciences (688837.SH) announced that the Company has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (NMPA). The Company's independently developed XNW26018 tablets have obtained clinical trial approval from the NMPA, and the Company plans to conduct clinical trials for the treatment of infectious diseases such as community-acquired pneumonia caused by microorganisms susceptible to this product. Community-acquired bacterial pneumonia (CABP) is one of the common infectious diseases, referring to infectious inflammation of the lung parenchyma contracted outside of hospitals. The disease has a relatively high incidence, especially among children and the elderly, with major pathogens including Streptococcus pneumoniae, Mycoplasma pneumoniae, Haemophilus influenzae, etc. XNW26018 tablets are a Class 1 innovative drug independently developed by Suzhou Evopoint Biosciences Pharmaceutical Technology Co., Ltd., with independent intellectual property rights, and belong to a novel macrolide antibiotic. Results from existing in vivo and in vitro studies show that this product has a broad antibacterial spectrum and favorable antibacterial properties, and can cover the main pathogenic bacteria spectrum of community-acquired bacterial pneumonia. It is intended for the treatment of infectious diseases such as community-acquired pneumonia caused by microorganisms susceptible to this product.